Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak Continues
- October 1, 2026
- Posted by: Chaitanya Auti
- Category: News
Alkem Laboratories Ltd. (ALKEM) has now traded within 2% of its 52-week low for its second straight session, with the stock down 1.32% across that stretch. At 9:52 AM IST, the share price was trading at Rs 4,929.10 after touching a low of Rs 4,879.85 during the day. The latest Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.
The previous close stood at Rs 4,965.15, while the stock opened at Rs 4,996.90 and touched the same level as its day high before easing lower. The company’s market capitalisation stood at Rs 59,722.72 crore. For a reader, the key point is not just the day’s slip, but the fact that the stock has remained near its 52-week trough across back-to-back sessions rather than in a one-off move.
Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak: Consecutive Low Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 4,929.1 |
| Previous Close | Rs 4,965.15 |
| Today's Move | Rs -36.05 (-0.73%) |
| Open | Rs 4,996.9 |
| High | Rs 4,996.9 |
| Low | Rs 4,879.85 |
| Market Capitalisation | Rs 59,722.72 crore |
Alkem Laboratories Ltd. (ALKEM) traded at Rs 4,929.1 versus the previous close of Rs 4,965.15, a fall of 0.73%. The stock opened at Rs 4,996.9, reached a high of Rs 4,996.9, touched a low of Rs 4,879.85.
Alkem Laboratories Ltd. (ALKEM) share price today is trading below the previous close, with the stock at Rs 4,929.10 versus Rs 4,965.15 earlier. That reflects a fall of Rs 36.05, or 0.73%, in the ongoing session. The intraday range has been Rs 4,996.90 on the high side and Rs 4,879.85 on the low side, which places the current price in the lower half of the day’s band. The stock had opened exactly at Rs 4,996.90, then moved lower, showing that the day’s early level did not hold.
The broader market-capitalisation read is Rs 59,722.72 crore, which keeps Alkem Laboratories Ltd. (ALKEM) among the larger listed names in the healthcare space. The present move should be read in the context of the repeated near 52-week low pattern rather than as a single-session event. That matters because the stock has stayed close to its yearly low for two sessions in a row, making the Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak the central market signal for readers tracking the share price, the stock performance and the current weakness in the counter.
Why Alkem Laboratories Ltd. (ALKEM) May Be Moving Today
According to recent news reports, Alkem Laboratories’ audit committee has authorised Grant Thornton to conduct a forensic audit over alleged fund misuse by a former employee. That development may be linked to the continued weakness in Alkem Laboratories Ltd. (ALKEM) share price, as such proceedings can keep governance and disclosure questions in focus. The news does not prove causation, but it coincides with the stock’s second straight near 52-week low reading and could be one factor investors are watching in the current stock news flow.
What the Repeated 52-Week Lows Show
The key message from the Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak is that the stock is not merely reacting to one intraday move. It has stayed within 2% of its one-year low for a second straight session, and the cumulative decline across that stretch is 1.32%. That repeated proximity to the yearly low suggests a persistent market preference for marking the stock lower, but the data available here stops short of confirming why that pattern has continued.
For investors tracking Alkem Laboratories Ltd. (ALKEM) stock analysis, the distinction matters. A one-day dip can be temporary, but a consecutive near-low pattern often becomes part of the broader share price update narrative. In this case, Univest data confirms the price pattern, while the cause remains unconfirmed. That is why the focus keyword for this event is not simply the share price, but the Alkem Laboratories Ltd. (ALKEM) Consecutive 52 Week Low trend.
Alkem Laboratories Ltd. (ALKEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 59,722.72 crore |
| P/E Ratio | 27.52x |
| P/B Ratio | 4.15x |
| ROE | 18.29% |
| ROCE | 21.28% |
| EPS | Rs 180.45 |
| Book Value Per Share | Rs 1,196.51 |
| Dividend Yield | 1.07% |
Alkem Laboratories Ltd. (ALKEM) fundamental metrics show P/E 27.52x, P/B 4.15x, ROE 18.29%, ROCE 21.28%. These figures provide context only and are not a buy or sell signal.
Alkem Laboratories Ltd. has a market capitalisation of Rs 59,722.72 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 27.52x, P/B at 4.15x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.29% and ROCE of 21.28%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 180.45, book value per share of Rs 1,196.51, dividend yield of 1.07%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.67x, median ROE of 11.23%, median ROCE of 13.17%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 27.52x |
| Benchmark Median P/E | 26.67x |
| Benchmark Average P/E | 38.83x |
| Benchmark P/E Range | 0x to 616.23x |
| Company P/B Ratio | 4.15x |
| Benchmark Median P/B | 2.67x |
| Company ROE | 18.29% |
| Benchmark Median ROE | 11.23% |
| Company ROCE | 21.28% |
| Benchmark Median ROCE | 13.17% |
| Company Market Capitalisation | Rs 59,722.72 crore |
| Benchmark Median Market Cap | Rs 768.75 crore |
Alkem Laboratories Ltd. (ALKEM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Alkem Laboratories Ltd. (ALKEM) has a P/E ratio of 27.52x, which is above the benchmark median of 26.67x, a difference of +3.19%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Alkem Laboratories Ltd. (ALKEM) has a ROE of 18.29%, which is above the benchmark median of 11.23%, a difference of +62.87%. Alkem Laboratories Ltd. (ALKEM) has a ROCE of 21.28%, which is above the benchmark median of 13.17%, a difference of +61.58%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd. | GLENMARK | 62,339.2 | 34.61 | 5.68 | 14.1 | 20.35 |
| Biocon Ltd. | BIOCON | 55,491.09 | 109.73 | 1.6 | 1.35 | 3.26 |
| Abbott India Ltd. | ABBOTINDIA | 54,909.79 | 33.88 | 10.57 | 34.67 | 46.72 |
| Gland Pharma Ltd. | GLAND | 49,952.91 | 42.75 | 4.54 | 10.56 | 14.96 |
| Ipca Laboratories Ltd. | IPCALAB | 46,049.85 | 37.13 | 5.73 | 15.88 | 19.41 |
Alkem Laboratories Ltd. (ALKEM) has a P/E ratio of 27.52x compared with the displayed peer median of 37.13x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.29% compares with a peer median of 14.1% across the companies shown in the table. ROCE stood at 21.28% versus the displayed peer median of 19.41%, providing a capital-efficiency comparison. Alkem Laboratories Ltd. (ALKEM) has a market capitalisation of Rs 59,722.72 crore. Among the 5 peers shown, only 1 has a larger market capitalisation.
Why Investors Are Watching
- The stock has traded within 2% of its 52-week low for a second straight session, keeping the near-low pattern in focus.
- The cumulative decline across the streak is 1.32%, which is more relevant than the day’s isolated move.
- The company’s P/E, P/B, ROE and ROCE suggest the decline is not being explained by weak profitability alone.
- The audit committee-approved forensic audit is a fresh development that may remain relevant for sentiment and stock news tracking.
- Investors may watch whether the share price continues to stay near the one-year low or starts trading away from it in the coming sessions.
About the Company
Alkem Laboratories Ltd. (ALKEM) is a pharmaceutical company listed on the NSE and BSE, operating in the healthcare sector under the pharmaceuticals & drugs industry. The company’s market capitalisation places it among the larger names in the space, and its financial metrics show a business with healthy returns on capital and equity. The current Alkem Laboratories Ltd. (ALKEM) share price update is therefore being viewed through both the stock price lens and the company’s fundamental profile.
For readers tracking Alkem Laboratories Ltd. (ALKEM) stock analysis, the important distinction is that the business metrics supplied here do not align with a distressed balance-sheet profile. At the same time, the stock price has remained near a yearly low for consecutive sessions, and that is what gives the present market update its significance. The current streak is about price behaviour, not a change in the company’s long-term business model.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does the Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak mean?
Ans. It means the stock has traded within 2% of its 52-week low for consecutive sessions. In this case, Alkem Laboratories Ltd. (ALKEM) has done so for a second straight session, which keeps the yearly-low pattern in focus.
How many sessions has Alkem Laboratories Ltd. (ALKEM) stayed near its low?
Ans. As per the latest Univest data, Alkem Laboratories Ltd. (ALKEM) has stayed within 2% of its 52-week low for two consecutive sessions. That is the key streak signal behind the current stock news.
Did the data confirm a company-specific reason for the decline?
Ans. No. The supplied information confirms the repeated near-low pattern, but it does not establish a company-specific cause. The news flow may be relevant, but the cause is not confirmed by the price data alone.
How does Alkem Laboratories Ltd. (ALKEM) look on valuation?
Ans. The stock trades at a P/E of 27.52 and a P/B of 4.15. On the supplied healthcare benchmark, that is slightly above the industry median P/E and well above the median P/B, while profitability remains stronger than the benchmark median.
How do Alkem’s profitability ratios compare with peers?
Ans. Alkem’s ROE of 18.29% and ROCE of 21.28% are above the industry median values in the supplied set. That suggests solid capital efficiency even as the share price remains near its 52-week low.
What recent news could matter for Alkem Laboratories Ltd. (ALKEM) stock?
Ans. The audit committee’s decision to approve a forensic audit by Grant Thornton over alleged fund misuse by a former employee may be relevant. It does not prove causation, but it is a notable development in the company news flow.
What should investors monitor next in Alkem Laboratories Ltd. (ALKEM) share price today?
Ans. Investors may track whether the stock continues to trade near the one-year low or begins moving away from that zone. The next reads on price, company news and the market’s response to the forensic audit will be important.
Track Alkem Laboratories Ltd. (ALKEM) Share Price on Univest
Use Alkem Laboratories Ltd. (ALKEM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.